crisugabalin
Jump to navigation
Jump to search
Indications
- neuropathic pain (approved in China, not yet FDA approved in U.S.)
Dosage
Adverse effects
- hyperuricemia
- hyperlipidemia
- urinary tract infection
- dizziness
- weight gain
- abnormal liver function tests
- somnolence
Mechanism of action
- third-generation gabapentinoid
- a highly seletive voltage-dependent Ca+2 channel alpha-2/delta ligand
More general terms
References
- ↑ Pan T, Ma J, Li Y, et al Rapid Onset of Pain Relief with Crisugabalin in Patients with Diabetic Peripheral Neuropathic Pain: Findings from a Multicenter, Randomized, Double-Blind, Controlled Study. Pain Ther. 2025 Aug;14(4):1311-1329 PMID: https://pubmed.ncbi.nlm.nih.gov/40377855 PMCID: PMC12279680 https://pmc.ncbi.nlm.nih.gov/articles/PMC12279680/
- ↑ Fu L, Xu N, Shang J, et al. Crisugabalin Combined with Acetyl-Levo-Carnitine for Diabetic Peripheral Neuropathic Pain: A Phase 2 Randomized Controlled Trial. J Pain Res. 2026 Apr 21;19:588472. PMID: https://pubmed.ncbi.nlm.nih.gov/42039234 PMCID: PMC13110016 https://pmc.ncbi.nlm.nih.gov/articles/PMC13110016/
- ↑ Zhang D. Lei T, Qin L, et al Efficacy and Safety of Crisugabalin (HSK16149) in Adults with Postherpetic Neuralgia. A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2024;160;(11):1182-1191 PMID: https://pubmed.ncbi.nlm.nih.gov/39320907 PMCID: PMC11581609 https://pmc.ncbi.nlm.nih.gov/articles/PMC11581609/
- ↑ Wikipedia: Crisugabalin https://en.wikipedia.org/wiki/Crisugabalin